Centro Hospitalar de Vila Nova de Gaia Espinho EPE, Vila Nova de Gaia, Portugal.
Champalimaud Foundation, Lisboa, Portugal
Int J Gynecol Cancer. 2023 Apr 3;33(4):607-618. doi: 10.1136/ijgc-2022-003719.
Advanced ovarian cancer remains a leading cause of death from gynecologic malignancy. Surgery and, in most cases, platinum-based chemotherapy with or without maintenance with bevacizumab and/or poly-ADP ribose polymerase inhibitors (PARPi) represent the mainstay of treatment, but the disease typically recurs. The treatment of these patients represents a clinical challenge because sequential chemotherapy regimens are often used, with suboptimal outcomes and cumulative toxicity. Chemotherapy-free regimens, based on combinations of PARPi, vascular endothelial growth factor receptor inhibitors, anti-programmed cell death protein-1/programmed death-ligand 1, and anti-cytotoxic T-lymphocyte-associated protein-4 antibodies, among others, represent a valid option, with manageable toxicity profile and ease of administration. This review addresses this new strategy in the management of recurrent ovarian cancer and discusses its feasibility in the treatment landscape of the disease.
高级别卵巢癌仍然是妇科恶性肿瘤死亡的主要原因。手术和（在大多数情况下）以铂类为基础的化疗联合或不联合贝伐珠单抗和/或聚 ADP 核糖聚合酶抑制剂（PARPi）维持治疗是主要治疗方法，但疾病通常会复发。这些患者的治疗是一个临床挑战，因为通常使用序贯化疗方案，疗效不佳且累积毒性增加。基于 PARPi、血管内皮生长因子受体抑制剂、抗程序性细胞死亡蛋白 1/程序性死亡配体 1 以及抗细胞毒性 T 淋巴细胞相关蛋白 4 抗体等药物联合的无化疗方案具有可管理的毒性特征和易于管理的特点，是一种有效的选择。本文综述了复发性卵巢癌管理中的这一新策略，并讨论了其在该疾病治疗领域中的可行性。
